218 related articles for article (PubMed ID: 36741723)
1. Efficacy of immunotherapy in
Peng L; Guo J; Kong L; Huang Y; Tang N; Zhang J; Wang M; He X; Li Z; Peng Y; Wang Z; Han X
Front Oncol; 2022; 12():1070761. PubMed ID: 36741723
[TBL] [Abstract][Full Text] [Related]
2. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
Iams WT; Balbach ML; Phillips S; Sacher A; Bestvina C; Velcheti V; Wang X; Marmarelis ME; Sethakorn N; Leal T; Sackstein PE; Kim C; Robinson MA; Mehta K; Hsu R; Nieva J; Patil T; Camidge DR
Clin Lung Cancer; 2023 May; 24(3):228-234. PubMed ID: 36841727
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of
Wang MM; Zhang Y; Wu S; Zhang SY; Shan HL; Yang XM; Xu X; Song LQ; Qu SY
Transl Lung Cancer Res; 2023 Oct; 12(10):2030-2039. PubMed ID: 38025817
[TBL] [Abstract][Full Text] [Related]
4. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
Chen H; Huang D; Lin G; Yang X; Zhuo M; Chi Y; Zhai X; Jia B; Wang J; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
Cancer Med; 2022 Oct; 11(19):3581-3592. PubMed ID: 35394121
[TBL] [Abstract][Full Text] [Related]
5. A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice.
Liu Y; Gao Y; Wang Y; Zhao C; Zhang Z; Li B; Zhang T
BMC Cancer; 2022 Nov; 22(1):1175. PubMed ID: 36376839
[TBL] [Abstract][Full Text] [Related]
6. KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China.
Li Q; Zhou Q; Zhao S; Wu P; Shi P; Zeng J; Xiong X; Chen H; Kittaneh M; Bravaccini S; Zanoni M; Zhou C; Zhang J
Transl Lung Cancer Res; 2022 Oct; 11(10):2136-2147. PubMed ID: 36386464
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis.
Chen J; Lu W; Chen M; Cai Z; Zhan P; Liu X; Zhu S; Ye M; Lv T; Lv J; Song Y; Wang D
Ther Adv Med Oncol; 2024; 16():17588359231225036. PubMed ID: 38420602
[TBL] [Abstract][Full Text] [Related]
8. A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations.
Lei L; Wang WX; Yu ZY; Liang XB; Pan WW; Chen HF; Wang LP; Fang Y; Wang M; Xu CW; Fang MY
Transl Oncol; 2020 Feb; 13(2):329-335. PubMed ID: 31881505
[TBL] [Abstract][Full Text] [Related]
9. Molecular Characteristics and the Effect of
Gu G; Yu B; Wan H; Lu S; Zhu X; Zhao Y; Fuxi Y; Liu C
Onco Targets Ther; 2022; 15():1021-1032. PubMed ID: 36172169
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of immunotherapy as second-line or later-line therapy and prognostic significance of KRAS or TP53 mutations in advanced non-small cell lung cancer patients.
Liu J; Gao J
Eur J Cancer Prev; 2023 Nov; 32(6):590-599. PubMed ID: 37038985
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Implication of
Noordhof AL; Swart EM; Damhuis RAM; Hendriks LEL; Kunst PWA; Aarts MJ; van Geffen WH
JTO Clin Res Rep; 2023 Sep; 4(9):100543. PubMed ID: 37674812
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis.
Gu X; Si J; Guan Y; Xu Y; Shao L; Zhang Y; Xu C; Pan W; Lu Y; Song Z; Wang W
Open Med (Wars); 2023; 18(1):20230653. PubMed ID: 36915627
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials.
Landre T; Justeau G; Assié JB; Chouahnia K; Davoine C; Taleb C; Chouaïd C; Duchemann B
Cancer Immunol Immunother; 2022 Mar; 71(3):719-726. PubMed ID: 34378081
[TBL] [Abstract][Full Text] [Related]
14. Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.
Julian C; Pal N; Gershon A; Evangelista M; Purkey H; Lambert P; Shi Z; Zhang Q
BMC Cancer; 2023 Apr; 23(1):352. PubMed ID: 37069542
[TBL] [Abstract][Full Text] [Related]
15. Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapy.
Bironzo P; Cani M; Jacobs F; Napoli VM; Listì A; Passiglia F; Righi L; Di Maio M; Novello S; Scagliotti GV
Cancer; 2023 Jun; 129(11):1662-1671. PubMed ID: 36905392
[TBL] [Abstract][Full Text] [Related]
16. Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond.
Gray JE; Hsu H; Younan D; Suri G; Chia V; Spira A; Johnson M
Lung Cancer; 2023 Jul; 181():107260. PubMed ID: 37285629
[TBL] [Abstract][Full Text] [Related]
17. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
[No Abstract] [Full Text] [Related]
18. The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer.
Liu L; Li F; Zhao J; Zhuo X; Lai J; Wang J; Jiang F; Xu W; Luan F; Lin X; Yang S; Fu G
J Cancer; 2023; 14(6):952-965. PubMed ID: 37151388
[No Abstract] [Full Text] [Related]
19. KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy.
Ghimessy AK; Gellert A; Schlegl E; Hegedus B; Raso E; Barbai T; Timar J; Ostoros G; Megyesfalvi Z; Gieszer B; Moldvay J; Renyi-Vamos F; Lohinai Z; Hoda MA; Klikovits T; Klepetko W; Laszlo V; Dome B
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31600989
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study.
Mazzaschi G; Perrone F; Minari R; Verzè M; Azzoni C; Bottarelli L; Pluchino M; Armillotta MP; Ubaldi A; Altimari A; Gruppioni E; Sperandi F; Andrini E; Guaitoli G; Bettelli S; Longo L; Bertolini F; Barbieri F; Pagano M; Bonelli C; Tagliavini E; Nicoli D; Ubiali A; Zangrandi A; Trubini S; Proietto M; Gnetti L; Tiseo M;
Clin Lung Cancer; 2022 Nov; 23(7):e478-e488. PubMed ID: 36002369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]